News
Abstract 3101: Zanzalintinib + Nivolumab ± Relatlimab in Patients with Advanced Solid Tumors: Results from Two Dose-Escalation Cohorts of the Phase 1b STELLAR 002 Study Lead Author: Benjamin Garmezy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback